Related Experiment Video
Updated: Aug 1, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD
Raj H Patel1, Pablo M Pella2, Naeem Haider3
1Edward Via College of Osteopathic Medicine, Monroe, LA, USA.
Insights
This case study shows successful treatment of COVID-19 in an End-Stage Renal Disease patient using remdesivir. Despite severe kidney impairment, the patient showed symptom improvement after antiviral therapy.
Area of Science:
- Nephrology
- Infectious Diseases
- Critical Care Medicine
Background:
- COVID-19 pandemic presents challenges in managing patients with End-Stage Renal Disease (ESRD).
- ESRD patients face higher risks for severe COVID-19 due to comorbidities.
- Limited data exists on remdesivir efficacy and safety in severe renal impairment due to exclusion from trials.
Observation:
- A 47-year-old male with ESRD and COVID-19 experienced worsening respiratory failure despite intensive care.
- Remdesivir was administered after risk-benefit analysis, despite an estimated glomerular filtration rate (eGFR) <15 ml/min per 1.73m².
- The patient developed reversible hepatotoxicity during treatment.
Findings:
- Successful treatment of COVID-19 in an ESRD patient with remdesivir.
- Marked symptom improvement observed post-five-day remdesivir course.
- Compassionate use of remdesivir demonstrated clinical benefit in a complex patient.
Implications:
- Suggests potential for remdesivir use in select ESRD patients with COVID-19 under careful monitoring.
- Highlights the need for further research into antiviral management for renal impairment patients.
- Provides evidence for compassionate use protocols in critical COVID-19 cases with comorbidities.
Background:
The novel coronavirus disease 2019 (COVID-19) has led to a global pandemic since its emergence from Wuhan, China, in December of 2019. As research continues to evolve, there is a paucity of reports describing the management and treatment of COVID-19 in patients with acute kidney failure and End-Stage Renal Disease (ESRD). These patients have increased susceptibility to developing severe clinical symptoms from SARS-CoV-2 infection due to their underlying comorbidities. Remdesivir has emerged as a promising antiviral drug against SARS-CoV-2. However, data regarding the clinical benefits of remdesivir in patients with severe renal impairment is unavailable as they have been excluded from clinical trials due to the risk of sulfobutylether-β-cyclodextrin (SBECD) accumulation in patients with eGFR<30 ml/min per 1.73m2.
Case Presentation:
We present the first case of a 47-year-old male with end-stage renal disease who was successfully treated with remdesivir during hospitalization for acute respiratory distress syndrome and respiratory failure arising from COVID-19. The worsening clinical progress of the patient despite intensive care and treatment with intravenous azithromycin therapy led to the decision to utilize remdesivir after a risk-benefit analysis, despite his eGFR being <15 ml/min per 1.73m2. Although the patient developed reversible hepatotoxicity, marked improvement of symptoms was observed after the five-day course of remdesivir was completed.
Conclusion:
Our findings describe the first instance of compassionate use of remdesivir for the treatment of COVID-19 in the setting of end-stage renal disease, acute respiratory distress syndrome, and hypoxemic respiratory failure.
More Related Videos
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome II : Assessment and Medical Management
Rocky Mountain Spotted Fever
Coronavirus
Respiratory Syncytial Virus Disease

